MedTrace Logo

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

NCT05073484 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-10-11

No results posted yet for this study

Summary

This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

BAT6021

Ⅳ infusions

DRUG

BAT1308

Ⅳ infusions

Sponsors & Collaborators

Principal Investigators

  • Abhijit Pal, M.D, Ph.D · Medical Oncologist at cancer Therapy, Liverpool Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05073484 on ClinicalTrials.gov